Pharming Group (PHAR)
NASDAQ:PHAR
Total Valuation
Pharming Group has a market cap or net worth of $1.21B. The enterprise value is $1.16B.
Market Cap$1.21B
Enterprise Value$1.16B
Share Statistics
Pharming Group has 70,625,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,625,230
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 0.97%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)0.97%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee933.62K
Profits Per Employee7.08K
Employee Count404
Asset Turnover0.75
Inventory Turnover0.70
Valuation Ratios
The current PE Ratio of Pharming Group is 55.3. Pharming Group’s PEG ratio is -3.57.
PE Ratio55.3
PS Ratio3.34
PB Ratio4.55
Price to Fair Value4.55
Price to FCF25.55
Price to Operating Cash Flow21.25
PEG Ratio-3.57
Income Statement
In the last 12 months, Pharming Group had revenue of 377.18M and earned 2.86M in profits. Earnings per share was 0.04.
Revenue377.18M
Gross Profit331.56M
Operating Income19.37M
Pretax Income12.88M
Net Income2.86M
EBITDA30.62M
Earnings Per Share (EPS)0.04
Cash Flow
In the last 12 months, operating cash flow was 49.38M and capital expenditures -753.96K, giving a free cash flow of 48.62M billion.
Operating Cash Flow49.38M
Free Cash Flow48.62M
Free Cash Flow per Share0.69
Dividends & Yields
Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change107.07%
50-Day Moving Average16.50
200-Day Moving Average14.92
Relative Strength Index (RSI)57.80
Average Volume (3m)21.09K
Important Dates
Pharming Group upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 41.79%
Current Ratio2.59
Quick Ratio2.03
Debt to Market Cap0.08
Net Debt to EBITDA-0.99
Interest Coverage Ratio0.91
Taxes
In the past 12 months, Pharming Group has paid 10.34M in taxes.
Income Tax10.34M
Effective Tax Rate0.80
Enterprise Valuation
Pharming Group EV to EBITDA ratio is 40.17, with an EV/FCF ratio of 24.94.
EV to Sales3.26
EV to EBITDA40.17
EV to Free Cash Flow24.94
EV to Operating Cash Flow24.57
Balance Sheet
Pharming Group has $179.81M in cash and marketable securities with $115.78M in debt, giving a net cash position of $64.03M billion.
Cash & Marketable Securities$179.81M
Total Debt$115.78M
Net Cash$64.03M
Net Cash Per Share$0.91
Tangible Book Value Per Share$1.98
Margins
Gross margin is 87.89%, with operating margin of 5.13%, and net profit margin of 0.76%.
Gross Margin87.89%
Operating Margin5.13%
Pretax Margin3.42%
Net Profit Margin0.76%
EBITDA Margin8.12%
EBIT Margin5.13%
Analyst Forecast
The average price target for Pharming Group is $39.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$39.00
Price Target Upside129.68% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast26.54%
EPS Growth Forecast―